November 2, 2021
To whom it may concern,
Company name: Konica Minolta, Inc.
Representative: Shoei Yamana, President and CEO
Stock Exchange Listing: Tokyo (First Section)
Local Securities Code Number: 4902
Contact: Mami Iwamoto, General Manager, Corporate Communications Division
Tel: (81) 3-6250-2111
Konica Minolta, Inc. (Konica Minolta) announces that its U.S. subsidiary, REALM IDx, Inc. (headquartered in California, USA, hereinafter referred to as "REALM IDx") is preparing for an IPO and listing in the United States. Konica Minolta will promptly provide details of the IPO as and when relevant decisions are made and as allowed by U.S. securities regulations.
About REALM IDx
REALM IDx is a consolidated subsidiary in the United States and operates as a holding company for the Precision Medicine business, with Ambry Genetics Corporation, Invicro, LLC and KONICA MINOLTA REALM, Inc., as its wholly-owned subsidiaries. Konica Minolta has decided to prepare for an IPO and listing in the United States in order to provide REALM IDx with the ability to raise funds for the future growth of this business.
Konica Minolta intends that REALM IDx will remain its consolidated subsidiary after the listing, as there will be no change in the business strategy positioning of its healthcare business.
- Name: REALM IDx, Inc.
- Address: 1 Enterprise, Aliso Viejo, CA 92656 U.S.A.
- Representative: CEO, Dr. Aaron Elliott
- Incorporation: October 2018
N.B.: REALM IDx changed its name from Konica Minolta Precision Medicine, Inc. to REALM IDx, Inc. on August 26, 2021. KONICA MINOLTA REALM, INC. changed its name from KONICA MINOLTA PRECISION MEDICINE JAPAN, INC. to KONICA MINOLTA REALM, INC. on October 15, 2021.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended ("Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.